GlassScriptPhysician profile
Aparna Ayyagari
NPI 1932364346
$5,492.76
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,045 · 2020: $356 · 2021: $764 · 2022: $1,379 · 2023: $1,549 · 2024: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $916.96 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $698.49 | 2019-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $448.79 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $262.12 | 2019-2023 | Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.89 | 2019-2024 | Jardiance |
| Amgen INC. | $239.07 | 2019-2023 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $199.84 | 2021-2024 | |
| Abbott Laboratories | $195.07 | 2019-2024 | Freestyle Libre 3, Penta |
| Glaxosmithkline, LLC. | $181.24 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Embecta Corp. | $171.10 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Insulet Corporation | $150.09 | 2019-2023 | Omnipod |
| Alexion Pharmaceuticals, INC. | $146.33 | 2019-2022 | |
| Abbvie INC. | $117.96 | 2019-2024 | |
| Dexcom, INC. | $99.55 | 2020-2024 | Dexcom G6 Transmitter |
| Mannkind Corporation | $96.45 | 2019-2023 | Afrezza |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aparna Ayyagari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.